Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

By D. Weber, Christine I. Chen, R. Niesvizky, Michael L. Wang, A. Belch, E. Stadtmauer, D. Siegel, I. Borrello, S. Rajkumar, A. Chanan-Khan and 6 more. New England Journal of Medicine, 2007

1,278 citations recorded by the source corpus.

Subfields: Hematology, Oncology

View Paper: https://www.semanticscholar.org/paper/277e618b5bf406bb4c476b3e3a54b42960f8e067

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. Michael R. Stratton
2. J. Baselga
3. A. Mantovani
4. Nathanael S. Gray
5. I. Stamenkovic
6. F. Balkwill
7. J. Settleman

In Oncology

1. A. Mantovani
2. A. Sica
3. P. Allavena
4. F. Balkwill
5. Michael R. Stratton
6. J. Baselga
7. Nathanael S. Gray
8. I. Stamenkovic

Citations in the corpus

• Systematic identification of genomic markers of drug sensitivity in cancer cells (2012, background): “Kidney (21) Lung (112) Other (19) Ovary (17) Pancreas (17) Skin (42) Soft tissue (18) Aero-digestive tract (45) Uterus (20) Thyroid (10)”
• Cancer-related inflammation (2008, background): “Also, a structural analogue of thalidomide, lenalidomide, that inhibits production of several inflammatory cytokines has been shown to be active against advanced myeloma when combined with dexamethason”